Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.